Aegis MedProtectCDM™ adherence monitoring gives clinicians a first-of-its-kind tool providing timely and objective insights to better manage individuals with chronic conditions such as; Hypertension, Type 2 Diabetes Mellitus, Dyslipidemia, and Chronic Obstructive
Pulmonary Disorder.
How are you evaluating and managing factors that are contributing to therapeutic nonresponse in at-risk individuals in your practice?
In a population that often requires multiple medications, nonadherence
and drug interactions can be major obstacles that are both difficult to identify and correct.
50%
Medication nonadherence is very common and affects up to 50% of individuals with chronic comorbid disease.11. Kleinsinger F. The Unmet Challenge of Medication Nonadherence. Perm J. 2018;22:18-033. doi:10.7812/TPP/18-033.
>100,000
Medication nonadherence is reported to contribute to over 100,000 preventable deaths annually.11. Kleinsinger F. The Unmet Challenge of Medication Nonadherence. Perm J. 2018;22:18-033. doi:10.7812/TPP/18-033.
$100 BIL.
Medication nonadherences contributes to significant preventable healthcare costs on an annual basis.11. Kleinsinger F. The Unmet Challenge of Medication Nonadherence. Perm J. 2018;22:18-033. doi:10.7812/TPP/18-033.
What is MedProtectCDM and What Disease States and Related Medications Are Monitored With This Test?
MedProtectCDM (Chronic Disease Management) is an oral fluid-based test that conveniently and objectively evaluates medication adherence and identifies Drug-Drug Interactions (DDI) to help tailor treatment plans and improve outcomes in patients with chronic conditions. Results of testing assist providers by:
- Objectively identifying medication nonadherence and clinically relevant DDIs
- Clearly showing opportunities to discuss adherence barriers, make safe and efficient treatment decisions, and optimize prescribing practices.
Compared to a control group, physicians using MedProtectCDM were
50.4x
More likely to recognize medication
nonadherence22. Peabody JW, Ganesan D, Valdenor C, et al. Randomized prospective trial to detect and distinguish between medication nonadherence, drug-drug interactions, and disease progression in chronic cardiometabolic disease. BMC Prim Care. 2023;24(1):100. Published 2023 Apr 15. doi:10.1186/s12875-023-02042-4 (Link: https://pubmed.ncbi.nlm.nih.gov/37061690/)
26.9x
More likely to identify a drug
interaction22. Peabody JW, Ganesan D, Valdenor C, et al. Randomized prospective trial to detect and distinguish between medication nonadherence, drug-drug interactions, and disease progression in chronic cardiometabolic disease. BMC Prim Care. 2023;24(1):100. Published 2023 Apr 15. doi:10.1186/s12875-023-02042-4 (Link: https://pubmed.ncbi.nlm.nih.gov/37061690/)
15.7x
More likely to make a prescription change
to resolve the interaction22. Peabody JW, Ganesan D, Valdenor C, et al. Randomized prospective trial to detect and distinguish between medication nonadherence, drug-drug interactions, and disease progression in chronic cardiometabolic disease. BMC Prim Care. 2023;24(1):100. Published 2023 Apr 15. doi:10.1186/s12875-023-02042-4 (Link: https://pubmed.ncbi.nlm.nih.gov/37061690/)
Clinical Utility
Studies have demonstrated positive impact in identification of both medication nonadherence and drug interactions. With results in hand, providers made improved decisions regarding care when nonadherence or interactions were identified.
Identifying and Managing Those at Risk
Differentiating disease progression from other factors that are contributing to missing treatment goals is challenging. Supplementing treatment decisions with objective information on nonadherence and drug interactions can assist in providing more effective care and realizing treatment goals.
Clarity in Results
Clear, concise reports are made available after collection and testing of noninvasive oral fluid specimens. Results not only provide information regarding recent use of prescription medication, but also identify common causes of drug interactions with details about potential outcomes.
- Clinical Utility
-
Clinical Utility
Studies have demonstrated positive impact in identification of both medication nonadherence and drug interactions. With results in hand, providers made improved decisions regarding care when nonadherence or interactions were identified.
- Identifying and Managing Those at Risk
-
Identifying and Managing Those at Risk
Differentiating disease progression from other factors that are contributing to missing treatment goals is challenging. Supplementing treatment decisions with objective information on nonadherence and drug interactions can assist in providing more effective care and realizing treatment goals.
- Clarity in Results
-
Clarity in Results
Clear, concise reports are made available after collection and testing of noninvasive oral fluid specimens. Results not only provide information regarding recent use of prescription medication, but also identify common causes of drug interactions with details about potential outcomes.
References:
1. Kleinsinger F. The Unmet Challenge of Medication Nonadherence. Perm J. 2018;22:18-033. doi:10.7812/TPP/18-033.
2. Peabody JW, Ganesan D, Valdenor C, et al. Randomized prospective trial to detect and distinguish between medication nonadherence, drug-drug interactions, and disease progression in chronic cardiometabolic disease. BMC Prim Care. 2023;24(1):100. Published 2023 Apr 15. doi:10.1186/s12875-023-02042-4 (Link: https://pubmed.ncbi.nlm.nih.gov/37061690/)
3. Valdenor C, Ganesan D, Paculdo D, et al. Clinical Variation in the Treatment Practices for Medication Nonadherence, Drug-Drug Interactions, and Recognition of Disease Progression in Patients with Chronic Cardiometabolic Diseases: A Cross-Sectional Patient Simulation Study among Primary Care Physicians. Int J Clin Pract. 2022;2022:6450641. Published 2022 Jul 30. doi:10.1155/2022/6450641 (Link: https://pubmed.ncbi.nlm.nih.gov/35989865/)
Reach out to Client Services to find out more
about utilizing this test in your practice today.
Client Services can be reached at client.services@aegislabs.com or 800.533.7052
